Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,026.02 +7.63 (+0.15%) Dow
37,983.02 +79.73 (+0.21%) Nasdaq
15,666.91 +61.42 (+0.39%) Bitcoin USD
58,508.29 +1,229.77 (+2.15%) CMC Crypto 200
1,259.39 -11.36 (-0.89%)
CLNN Jun 2024 2.000 put
| Previous close | 1.6500 |
| Open | N/A |
| Bid | 1.5500 |
| Ask | 1.7000 |
| Strike | 2.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.6500 - 1.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireIBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ: CLNN), recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, ho
Simply Wall St.Bullish Clene Insiders Loaded Up On US$9.58m Of Stock
Quite a few insiders have dramatically grown their holdings in Clene Inc. ( NASDAQ:CLNN ) over the past 12 months. An...
GlobeNewswireEvidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Long term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05)Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8® 30 mg treatment (change from original baseline; p<0.05)Long-term CNM-Au8 treatment, encompassing up to three years, was well-tolerated; no significant safety findings were observedFirst Phase 2 clini
